GlassScriptPhysician profile
James B Caldwell
NPI 1639186513
$1,790.07
in general payments reported to CMS, 2019-2025
14 companies · $424 in 2025
The $424 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $159 · 2021: $220 · 2022: $191 · 2023: $150 · 2024: $496 · 2025: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,070.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,069.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $495.87 | 2024-2025 | Apligraf |
| Leo Pharma INC. | $341.28 | 2019-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $204.28 | 2020-2025 | |
| Pfizer INC. | $181.09 | 2019-2022 | |
| Biofrontera INC. | $137.71 | 2021-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Kerecis Limited | $102.82 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Galderma Laboratories, L.P. | $77.58 | 2020-2025 | Nemluvio |
| Almirall LLC | $76.16 | 2022-2024 | Klisyri |
| Regeneron Healthcare Solutions, INC. | $71.39 | 2020-2021 | |
| Mayne Pharma Commercial LLC | $24.24 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $21.51 | 2019 | |
| Incyte Corporation | $20.93 | 2023 | Opzelura |
| Vyne Pharmaceuticals INC. | $19.86 | 2021 | |
| Taro Pharmaceuticals USA, INC. | $15.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Caldwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.